| Upadacitinib | 380.375
C17H19F3N6O |  | An oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies. | Selective Immunosuppressants |
| Omidenepag isopropyl | 520.61
C26H28N6O4S |  | An agonist of the prostaglandin EP2 receptor indicated for the reduction of elevated intraocular pressure. | Antiglaucoma Agents / Hypotensive Agents / Ophthalmic Solutions / Ophthalmics / Prodrugs / Pyrazoles / Pyridines / Receptors, Prostaglandin E, EP2 Subtype, agonists / Sulfonamides |
| Aprocitentan | 546.19
C16H14Br2N6O4S |  | An endothelin receptor antagonist used for the treatment of uncontrolled hypertension in patients inadequately controlled on other treatments. | Amides / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / BSEP/ABCB11 Inhibitors / Cytochrome P-450 CYP2C18 Inhibitors / Cytochrome P-450 CYP2C18 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Endothelin Receptor Antagonists / P-glycoprotein substrates / Sulfones / Sulfur Compounds / UGT1A1 Inhibitors / UGT1A1 Substrates / UGT2B7 Inhibitors / UGT2B7 substrates |
| Zanubrutinib | 471.561
C27H29N5O3 |  | A kinase inhibitor used to treat mantle cell lymphoma, a type of B-cell non-Hodgkin lymphoma, in adults who previously received therapy. | Bruton's tyrosine kinase (BTK) inhibitors / Tyrosine Kinase Inhibitors |
| Daridorexant | 450.93
C23H23ClN6O2 |  | A dual orexin receptor antagonist used to treat insomnia in adults. | Orexin Receptor Antagonists |
| Avacopan | 581.656
C33H35F4N3O2 |  | An orally bioavailable complement 5a receptor (C5aR) antagonist for the treatment of severe anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis. | Selective Immunosuppressants |
| Umbralisib | 571.56
C31H24F3N5O3 |  | A kinase inhibitor used to treat rare forms of refractory lymphoma. | Kinase Inhibitor |
| Voxelotor | 337.379
C19H19N3O3 |  | A drug used to inhibit the polymerization of hemoglobin S, preventing the painful and sometimes lethal vaso-occlusive crises associated with sickle cell disease. | Hematologic Agents |
| Abrocitinib | 323.42
C14H21N5O2S |  | A kinase inhibitor used to treat moderate-to-severe atopic dermatitis in adults. | Agents for Dermatitis, Excluding Corticosteroids |
| Ritlecitinib | 285.351
C15H19N5O |  | A kinase inhibitor used to treat severe alopecia areata in adults and adolescents 12 years and older. | Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Immunomodulatory Agents / Immunosuppressive Agents / Janus Kinase 3, antagonists & inhibitors / Janus Kinase Inhibitors / Janus Kinases, antagonists & inhibitors |
| Mavacamten | 273.336
C15H19N3O2 |  | A myosin inhibitor used to treat obstructive hypertrophic cardiomyopathy. | Amines / Benzene Derivatives / Benzyl Compounds / Cardiac Myosin Inhibitor / Cardiac Therapy / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Pyrimidines / Pyrimidinones |
| Flortaucipir F-18 | 262.278
C16H10FN3 |  | A small lipophilic tracer containing [18F]fluoride capable of crossing the blood-brain barrier and binding to aggregated tau protein; used in PET imaging for the diagnosis of Alzheimer's disease. | Contrast Media |
| Vibegron | 444.535
C26H28N4O3 |  | A beta-3 adrenergic agonist the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. | Adrenergic Agonists / Adrenergic beta-3 Receptor Agonists / Adrenergic beta-Agonists / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Urinary Frequency and Incontinence / Genitourinary Smooth Muscle Relaxants / P-glycoprotein substrates / Pyrimidines / Selective Beta 3-adrenergic Agonists |
| Oliceridine | 386.55
C22H30N2O2S |  | A biased opioid agonist indicated for the management of severe acute pain in adult patients. Through preferential activation of G-protein-coupled signalling pathways, oliceridine provides analgesic effect with a comparable or improved safety profile over conventional opioid agonists. | Ligands |
| Cefiderocol | 752.21
C30H34ClN7O10S2 |  | A cephalosporin antibiotic used in complicated urinary tract infections. | beta Lactam Antibiotics |
| Filgotinib | 425.51
C21H23N5O3S |  | A Janus kinase (JAK) 1 selective inhibitor used to treat cases of rheumatoid arthritis that are unresponsive to conventional treatments. | Selective Immunosuppressants |
| Ripretinib | 510.367
C24H21BrFN5O2 |  | A kinase inhibitor used to treat advanced gastrointestinal stromal tumor (GIST). | Kinase Inhibitor |
| Piflufolastat F 18 | 441.403
C18H23FN4O8 |  | A radiopharmaceutical diagnostic agent used with PET to image PSMA-positive lesions for the diagnosis of metastatic or recurrent prostate cancer. | Fluorine Radioisotopes / Radioactive Diagnostic Agent |
| Diroximel fumarate | 255.226
C11H13NO6 |  | A drug used for the treatment of relapsing forms of Multiple Sclerosis (MS). | Acids, Acyclic / Antineoplastic and Immunomodulating Agents / Dicarboxylic Acids / Fumarates / Hepatotoxic Agents / Immunosuppressive Agents |
| Etrasimod | 457.493
C26H26F3NO3 |  | An S1P receptors modulator used to treat moderate to severely active ulcerative colitis in adults | Acids, Acyclic / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fatty Acids / Fatty Acids, Volatile / Heterocyclic Compounds, Fused-Ring / Lipids |
| Cycloguanil | 251.715
C11H14ClN5 |  | Cycloguanil is the active metabolite of proguanil. | Biguanides |
| Remdesivir | 602.585
C27H35N6O8P |  | A nucleoside analog used to treat RNA virus infections including COVID-19. | Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors |
| Solriamfetol | 194.234
C10H14N2O2 |  | Solriamfetol is indicated for treatment of daytime sleepiness associated with obstructive sleep apnea and narcolepsy, but is not a treatment for the underlying airway obstruction in apnea patients[FDA Label][A176534,A176744]. | Centrally Acting Sympathomimetics |
| Hydroxystilbamidine | 280.331
C16H16N4O |  | Used in the treatment of nonprogressive blastomycosis of the skin and other mycoses. | Amidines / Benzene Derivatives / Benzylidene Compounds / Stilbenes |
| Racephedrine | 165.236
C10H15NO |  | Not Annotated | Adrenergic Agonists / Adrenergic alpha-Agonists / Adrenergic beta-Agonists / Alpha-and Beta-adrenergic Agonists / Herbs and Natural Products / Norepinephrine Releasing Agents / Sympathomimetic (Adrenergic) Agents |
